Phase 4
Completed N=71
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
Source: ClinicalTrials.gov NCT00259649 ↗Enrolled (actual)
71
Serious AEs
0.0%
Results posted
Jul 2011
Primary outcomePrimary: Change in Mean Headache Index Score Among Patients — -1.52 headache index score
Summary
Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mean Headache Index Score Among Patients |
-1.52 | — |
Eligibility Criteria
Inclusion Criteria
- age 18-45 healthy menstruating female
Exclusion Criteria
- cardiac or other conditions precluding use of eletriptan
Data sourced from ClinicalTrials.gov (NCT00259649). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.